Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 109,675 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 109,675 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $6.30, for a total value of $690,952.50. Following the transaction, the insider directly owned 15,010,284 shares of the company’s stock, valued at $94,564,789.20. The trade was a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.20, for a total value of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.10, for a total value of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.07, for a total value of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Price Performance

Shares of VIR opened at $6.12 on Thursday. The firm has a market cap of $850.19 million, a P/E ratio of -1.53 and a beta of 1.27. The stock has a 50 day simple moving average of $5.27 and a two-hundred day simple moving average of $5.28. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The firm had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm’s quarterly revenue was down 60.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.02) EPS. On average, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on VIR shares. Evercore ISI started coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price for the company. Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and upped their target price for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Tuesday, October 14th. Raymond James Financial started coverage on Vir Biotechnology in a research note on Friday, July 11th. They set an “outperform” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.30.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in VIR. GAMMA Investing LLC raised its holdings in shares of Vir Biotechnology by 524.3% during the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after acquiring an additional 5,972 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Vir Biotechnology during the first quarter valued at approximately $78,000. Principal Financial Group Inc. raised its holdings in shares of Vir Biotechnology by 2.7% during the first quarter. Principal Financial Group Inc. now owns 459,337 shares of the company’s stock valued at $2,977,000 after acquiring an additional 12,024 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Vir Biotechnology during the first quarter valued at approximately $97,000. Finally, CWM LLC raised its holdings in shares of Vir Biotechnology by 1,160.2% during the first quarter. CWM LLC now owns 17,554 shares of the company’s stock valued at $114,000 after acquiring an additional 16,161 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).